Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024
5
Ṁ110Ṁ152resolved Jan 2
Resolved
NO1H
6H
1D
1W
1M
ALL
The reporting must be within 2024, so if the reporting happens in January 2025 regarding Q4 2024, then this still resolves NO.
This question is managed and resolved by Manifold.
Market context
Get 
1,000 to start trading!
1,000🏅 Top traders
| # | Trader | Total profit |
|---|---|---|
| 1 | Ṁ46 | |
| 2 | Ṁ3 |
Sort by:
Best data I could find indicated about 1.8% of the US population on a GLP-1. The actual number may be higher, but per the definition, we need reporting.
@DavidFWatson Agreed, although the number of Americans taking GLP-1s may well exceed the threshold, I agree that there is no reliable reporting suggesting it is, the survey data available is not sufficient to establish.
People are also trading
Related questions
What fraction of US adults will regularly take GLP-1 drugs in 2030?
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
88% chance
Will a majority government owned company introduce a new GLP-1 drug before 2040?
16% chance
By 2029, will there be an FDA approval of GLP-1 for a substance use disorder?
51% chance
Will Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?
45% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
10% chance
Clinical trial shows by 2030 that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms
74% chance
More than 30% of US citizens will be on prescription drugs for weight loss by 2031
22% chance
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Will there be medical consensus that GLP-1 drugs have cardiovascular benefits beyond those provided via weight loss?
75% chance